{"name":"Formosa Pharmaceuticals, Inc.","slug":"formosa-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"Formosa Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative treatments for various medical conditions. The company's pipeline includes three drug candidates in different phases of clinical development, with a strong emphasis on dermatological applications.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"APP13007, 0.05%","genericName":"APP13007, 0.05%","slug":"app13007-0-05","indication":"Glaucoma","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"APP13007, 0.1%","genericName":"APP13007, 0.1%","slug":"app13007-0-1","indication":"Type 2 diabetes","status":"phase_2"}]}],"pipeline":[{"name":"APP13007, 0.05%","genericName":"APP13007, 0.05%","slug":"app13007-0-05","phase":"phase_3","mechanism":"APP13007 is a topical ophthalmic agent designed to reduce intraocular pressure in glaucoma and ocular hypertension.","indications":["Glaucoma","Ocular hypertension"],"catalyst":""},{"name":"APP13007, 0.1%","genericName":"APP13007, 0.1%","slug":"app13007-0-1","phase":"phase_2","mechanism":"APP13007 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-02-23","type":"pipeline","source":"PR Newswire","summary":"Formosa Pharmaceuticals Announces Licensing Agreement with Arrotex, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Sur","headline":"Formosa Pharmaceuticals Announces Licensing Agreement with Arrotex, for Commercialization of Clobetasol Propionate Ophth","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-12","type":"pipeline","source":"PR Newswire","summary":"Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and P","headline":"Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNSF9tMkJVVGJwNEhxUHlUSnZpMlN1VjlQTUVnTWVWajJscjhVZTdoVHBzdDNNeC0zLXpPTGV0cGQ2VFprSkQwaW9MTm1hcjAzSVRWa293Yk8ya2J4UzlPSE8ya19aUnVsZVVtcUlta1NkRmZGMTgzNm8xY2UwMkhKUW9IS0FVc1ZmLXEw?oc=5","date":"2025-12-04","type":"pipeline","source":"Pharmaceutical Technology","summary":"Formosa and Rxilient sign licensing agreement for APP13007 - Pharmaceutical Technology","headline":"Formosa and Rxilient sign licensing agreement for APP13007","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-03","type":"pipeline","source":"PR Newswire","summary":"Formosa Pharmaceuticals Announces Licensing Agreement with Rxilient, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Su","headline":"Formosa Pharmaceuticals Announces Licensing Agreement with Rxilient, for Commercialization of Clobetasol Propionate Opht","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAJBVV95cUxNWWo0cVVMUWZiRUVFOGZpcDhFd2xYNmN4UGZzb0oxWFo5QjhLMktYTVdfZkVVLWljT3hmRnFsSFVpNWdpOG5FXzdqX3BqdUZGX0ZoeGcwSlV3Z201QXVRalVIY1JSZ2dNTFhCdk5UazZMNWkydEExUlVmVGNaZDJSQXJtNVU1c05OOEQ1ZDJ3eUFRSkd6SlBLREpxQ0VJT0tJV3ZVWnQ1WTR1V1hjZFdnamRHVzVzMmpBdnctLUtTV1BqY2lvTkduYlJ6Qjc1OVZfaUxySWttXzlIbkQ0Tm9RRjZCdHlhc2tkaVpibDdYNXBzQXkyZGZDbGVFNDhfZVctclFOaUJMaDhKcW5oZDhOMWtWMXBTODc0U3RnV1lOX0sxaHBSQVEzRnRXQTg2X1FmRF9wRmtZYXFQdjZ2eE8xNUNBQjVWY19K?oc=5","date":"2025-05-28","type":"pipeline","source":"PR Newswire","summary":"Formosa Pharmaceuticals and Adalvo Limited Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain - PR Newswire","headline":"Formosa Pharmaceuticals and Adalvo Limited Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxONHVpVFhGUnlRcDZEcDNFc096TkNqSGZoQlR5UlluYlduU2NVQkhJaTZCaUJpNXBfMThpaGp3WVpTRnFfcG1lZmFzM1FndzdtbFhKVHFYMk12NFFEcmlhNEFJY2ZfcXFaNlppeDl5R1VRSkMxYWMzb1RSX1prNDBGMmt3QTJpVUhReXFBS0FjdVFiU0hNc0FnNXRObTFQd1VyYktBNUxPUVZ5U2VwaGRhdTUyV0Q0ei03bzdjS0dzYzNHSC11YmkzVQ?oc=5","date":"2024-11-06","type":"trial","source":"Ophthalmology Times","summary":"Formosa Pharmaceuticals announces top-line results from Chinese trial evaluating APP13007 - Ophthalmology Times","headline":"Formosa Pharmaceuticals announces top-line results from Chinese trial evaluating APP13007","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNMy1DakVyV2NqeC00MkZIYnV4MDN5d0tyTUpKZWpnTHduTEJuVmJqTzdlbUw2dTlHdnpRQ2FzU0dZWEx5TDVjUWtDWUY3cVhHS0l2X1N0YTJiRllNY2wzS1Fxa2RjZ1ZReUhpY2wwd2VwR2gwZ3NvZU9ndmFjMkhIVS1SLTZIQU9yMno5dDdQcU9yOWZoLUhUdURmYVdkRUxDdGF3WUlzSFgzZHhpb1hRVWxIZ1BTYklLY0dlYTl0QkxSZw?oc=5","date":"2024-09-09","type":"pipeline","source":"Ophthalmology Times","summary":"Formosa Pharmaceuticals makes first shipment of APP13007 to US for commercialization - Ophthalmology Times","headline":"Formosa Pharmaceuticals makes first shipment of APP13007 to US for commercialization","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE4xOXFNc2JIcHhvM1ppNloyejVMdHFYYkowcFRXcUNVQ0d1Y3BhdlV0enJHbUsxbUVFLU1xX1Z2aTBHV1NaeEtRbURxcW42UGFUbTNHZVVLdnc3aXlKZS16Zy1xZ2tRSzJndlFfWWZpbllBMFdOZkN6OC1Ddkc2b00?oc=5","date":"2024-09-09","type":"pipeline","source":"Pharmaceutical Technology","summary":"Formosa Pharma ships APP13007 ophthalmic drug to US - Pharmaceutical Technology","headline":"Formosa Pharma ships APP13007 ophthalmic drug to US","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxNNWtwZWVKRTh5bkVUWFFGbG1haFdIOHdjZnRXMDE5T0hZVm50WUJyUmFRVWg3N3JaY2RKellFREltRC10VFBlcWtxUFl4cUhFUnF2Y1FFTHBfa29ueHRuc3Zza2dqdm5faGFRMEFzNnNXN0pZRXpsQ21LWTBlY3J1d2JHUlFRTHpmVmdBYlRkRDFXaHo5TFhqQ25YRmI2MU1adG82cHJNQ3JCWWpEeEM4TFVzSkVXcjBRdGd5b2xCYWJsZnFPM01qMThNVXVDMzUybUc2LUQwbkt2NmwzNV9FaklKbDFrZFVzMEx6a1dBTHM2TDJjT2s5Uk40dS0tZzVUcHROX0lFQzh4SENURzJpakY4RjljS0NQZC1jdUFVSzJVOWNkUU5IUG93?oc=5","date":"2024-08-07","type":"pipeline","source":"BioSpace","summary":"Formosa Pharma and Eyenovia Announce Initiation of Co-Development of Clobetasol Propionate Ophthalmic Suspension, 0.05%, for the treatment of Acute Dry Eye Disease in United States - BioSpace","headline":"Formosa Pharma and Eyenovia Announce Initiation of Co-Development of Clobetasol Propionate Ophthalmic Suspension, 0.05%,","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxNYlZ3QUV1V0F6d243Y2h5N2N5N19kOTZQdzZrZGhrRUxIX1dldHMxVzBIOEpvWVRJSDRnNnYwNXo4QTNqUkFHTXA2cGJfQ0RkNVNEcGk5WnUxSDhIcmthVkh3QTlvX2I1Y0ZibjNpOFRuRDMyUHFjUm1lQzVnSlREekJIRno1WHBtWW1EdURFTWZ6NFlyTGR4VGkyV2V1ZTdiYzNVWnNOVVB6and1VnNQM3lOclNLU19GeHN1cWp6a2dGTzhpSnZUaw?oc=5","date":"2024-08-07","type":"pipeline","source":"Ophthalmology Times","summary":"Formosa Pharmaceuticals and Apotex Inc. announce licensing agreement of APP13007 in Canada - Ophthalmology Times","headline":"Formosa Pharmaceuticals and Apotex Inc. announce licensing agreement of APP13007 in Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wJBVV95cUxPeTJycXZsRXIyY0JQSFYtcEluLUNEdVMwNXozWFQxSktVd3kyTS0wRGlOT2s0RVVwWWt2UlVHMDBGRzg1M0p2Z01haUM3S2JuenZpT25pYjgxSVI0TzBwc2lESFNuSEkyRzlmVUFyZXgyQktrYzRGQUFWMHl6QThaZ1p4NXNpZEhsRHZtOW5iYjYyeFg2SFV2enVhUFNyM1JDTXZJdjlaVnhsdHN5MTBKTWg5VkZyUDlIdnhLN3VNa0Y0NW9oUXRYa1FURlVPWmVmT3lmVmNnSlhJS2p5VGFvaFRlZUdlRG43U01TMENKZHZIMlJablhMV09PUUV6VjhEcXBjTjBwN0cxVExkNDIwazMxdm5jQ0tjejNmcmVBT1pzdUo5OU93b2FaZ3dwbFgyTUhUbjZyVWF0VHB6blpqVER6UWF1MmRSUktoem9EYkczTXlkMzcxcWZuUjZDbGs?oc=5","date":"2024-05-09","type":"pipeline","source":"BioSpace","summary":"Formosa Pharmaceuticals Announces Licensing Agreement with Tabuk Pharmaceuticals, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Follow","headline":"Formosa Pharmaceuticals Announces Licensing Agreement with Tabuk Pharmaceuticals, for Commercialization of Clobetasol Pr","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxNU3QyVkw3dFhTM0NvempMYTRwVXUwcVJsa0tLQmxkVXdCbnIwaXZCOE1YNUVPd2stSy1ZR3FncWgyQUxfSUc1ZDFUVC1KR1VQSlpLOHZueDBSNGMwSlVsM2FLQkdGU1o4U1E4dXQ1RkJqQUVuRjJrenpGV2pWXzIzNERxeE00Q0stR1BDc3hCSFJvVmNJTWJ1V1R1dWt6QU9BMmljR0JxNXlER0tSQ1JqdExSRHlhV0VNVGJqbVRkZmk0RmNV?oc=5","date":"2024-03-04","type":"regulatory","source":"Reuters","summary":"US FDA approves Eyenovia's eye drug, Formosa Pharma says - Reuters","headline":"US FDA approves Eyenovia's eye drug, Formosa Pharma says","sentiment":"positive"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"phase_2":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}